A leading provider of
innovative DNA Screening solutions
AML Breakapart LPH027
The AML1 (CBFA2 or RUNX1) gene is the most frequent target of chromosomal rearrangements observed in human acute leukemia. The most common rearrangements are the TEL/AML and AML/ETO fusions which provide for a favourable outcome whilst the TEL/AML1 fusion is associated with late relapse.
The AML1 gene is also involved in many other rare translocations including the partner chromosomes - 1, 2, 3, 4, 6, 9, 16, 20 and X. AML1 has also been found amplified in childhood ALL and is associated with a poorer outcome.
The Cytocell AML1 breakapart product has been designed to show gross changes in the AML1 gene without prior knowledge of any involvement of partner chromosome(s) as a rearrangement will be clearly visible in non-dividing cells as well as those at metaphase.
AML Breakapart Probe
Cat. No. LPH 027-S (5 tests)
Cat. No. LPH 027 (10 tests)
This webpage could contain information on product details or information not valid in your country or region. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration or usage in the country of your origin. If you are a resident of a country other than those to which this site is directed, contact your local Cytocell distributor to obtain the appropriate product information for your country of residence.
Developed &produced in the UK